LISBON — Long-term treatment with low-molecular-weight heparin during pregnancy did not cause a drop in spinal bone mineral density in a study with 62 women, Dr. Marc A. Roger said at the third World Congress of the International Society of Obstetric Medicine.
The findings are from a subgroup analysis of data collected in the Thrombophilia in Pregnancy Prophylaxis Study (TIPPS), an ongoing, multicenter trial designed to compare prophylaxis using LMWH with placebo for pregnancy outcomes in women with a thrombophilia, explained Dr. Roger, Ottawa Hospital.
TIPPS enrolled women with thrombophilia at less than 20 weeks gestation who were at risk for thromboembolism or had a history of pregnancy complications. They were randomized to placebo or to 5,000 U dalteparin daily through week 20, followed by a regimen of 5,000 U b.i.d. through delivery. All women in the study received dalteparin post partum for 6 weeks. In the substudy of 62 women, the primary end point was the absolute lumbar-spine bone mineral density measured at 6 weeks post partum. Because of crossovers, 33 women received dalteparin and 29 women received placebo.
The average bone mineral density was 1.15 g/cm